Beijing Tiantan Biological Products (SHSE:600161) Cyclically Adjusted Revenue per Share: ¥2.23 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600161 Beijing Tiantan Biological Products Corp Ltd SHSE:600161
69 GF Score
Price ¥12.78
GF Value ¥22.93
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Beijing Tiantan Biological Products Cyclically Adjusted Revenue per Share?

Beijing Tiantan Biological Products SHSE:600161 -1.16% 69 Cyclically Adjusted Revenue per Share is ¥2.23 as of Mar. 2026. GuruFocus rates SHSE:600161 with a GF Score™ of 69/100 and a GF Value™ of ¥22.93 (Significantly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Beijing Tiantan Biological Products's adjusted revenue per share for the three months ended in Mar. 2026 was ¥0.544. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ¥2.23 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Beijing Tiantan Biological Products's average Cyclically Adjusted Revenue Growth Rate was 10.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 10.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 9.80% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 11.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Beijing Tiantan Biological Products was 17.40% per year. The lowest was 9.30% per year. And the median was 12.30% per year.

As of today (2026-08-04), Beijing Tiantan Biological Products's current stock price is ¥12.78. Beijing Tiantan Biological Products's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ¥2.23. Beijing Tiantan Biological Products's Cyclically Adjusted PS Ratio of today is 5.73.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Beijing Tiantan Biological Products was 27.14. The lowest was 5.12. And the median was 12.78.


Beijing Tiantan Biological Products  (SHSE:600161) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Beijing Tiantan Biological Products's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=12.78/2.23
=5.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Beijing Tiantan Biological Products was 27.14. The lowest was 5.12. And the median was 12.78.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Beijing Tiantan Biological Products Cyclically Adjusted Revenue per Share Related Terms


Beijing Tiantan Biological Products Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Beijing Tiantan Biological Products's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Tiantan Biological Products Cyclically Adjusted Revenue per Share Chart

Beijing Tiantan Biological Products Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.50 1.64 1.77 1.96 2.18

Beijing Tiantan Biological Products Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.01 2.06 2.11 2.18 2.23

SHSE:600161 vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Beijing Tiantan Biological Products's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Tiantan Biological Products Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beijing Tiantan Biological Products's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Beijing Tiantan Biological Products's Cyclically Adjusted PS Ratio falls into.


SHSE:600161
69GF Score
Beijing Tiantan Biological Products Corp Ltd SHSE:600161
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beijing Tiantan Biological Products Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Beijing Tiantan Biological Products's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.544/116.3033*116.3033
=0.544

Current CPI (Mar. 2026) = 116.3033.

Beijing Tiantan Biological Products Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.310 101.400 0.356
201609 0.257 102.400 0.292
201612 0.405 102.600 0.459
201703 0.296 103.200 0.334
201706 0.274 103.100 0.309
201709 0.324 104.100 0.362
201712 0.487 104.500 0.542
201803 0.315 105.300 0.348
201806 0.360 104.900 0.399
201809 0.464 106.600 0.506
201812 0.492 106.500 0.537
201903 0.404 107.700 0.436
201906 0.455 107.700 0.491
201909 0.538 109.800 0.570
201912 0.440 111.200 0.460
202003 0.439 112.300 0.455
202006 0.436 110.400 0.459
202009 0.599 111.700 0.624
202012 0.437 111.500 0.456
202103 0.465 112.662 0.480
202106 0.372 111.769 0.387
202109 0.757 112.215 0.785
202112 0.640 113.108 0.658
202203 0.375 114.335 0.381
202206 0.554 114.558 0.562
202209 0.513 115.339 0.517
202212 0.685 115.116 0.692
202303 0.658 115.116 0.665
202306 0.719 114.558 0.730
202309 0.663 115.339 0.669
202312 0.576 114.781 0.584
202403 0.617 115.227 0.623
202406 0.832 114.781 0.843
202409 0.607 115.785 0.610
202412 0.984 114.893 0.996
202503 0.648 115.116 0.655
202506 0.934 114.907 0.945
202509 0.665 115.471 0.670
202512 0.876 115.832 0.880
202603 0.544 116.303 0.544

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ¥2.23 mean?
Beijing Tiantan Biological Products (SHSE:600161) has a Cyclically Adjusted Revenue per Share of ¥2.23 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Beijing Tiantan Biological Products and its competitors.
Is Beijing Tiantan Biological Products' Cyclically Adjusted Revenue per Share too high?
Beijing Tiantan Biological Products' current Cyclically Adjusted Revenue per Share is ¥2.23. Overall, Beijing Tiantan Biological Products has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beijing Tiantan Biological Products' Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Beijing Tiantan Biological Products' Cyclically Adjusted Revenue per Share of ¥2.23 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Beijing Tiantan Biological Products and its competitors. Beijing Tiantan Biological Products's current Cyclically Adjusted Revenue per Share is ¥2.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Tiantan Biological Products stock overvalued right now?
Based on GuruFocus' analysis, Beijing Tiantan Biological Products (SHSE:600161) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥22.93, compared to a current price of ¥12.78 — trading 44.3% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ¥2.23. Beijing Tiantan Biological Products' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Beijing Tiantan Biological Products (SHSE:600161), the current Cyclically Adjusted Revenue per Share is ¥2.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beijing Tiantan Biological Products (SHSE:600161) Overvalued in 2026?

Based on GuruFocus' analysis, Beijing Tiantan Biological Products stock appears to be undervalued. The current stock price of ¥12.78 is trading 44.3% below its estimated GF Value™ of ¥22.93. GuruFocus considers Beijing Tiantan Biological Products to be Significantly Undervalued.

Key valuation signals for SHSE:600161:

  • Cyclically Adjusted Revenue per Share: ¥2.23
  • GF Value™: ¥22.93 vs. price of ¥12.78 (44.3% below fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the SHSE:600161 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Beijing Tiantan Biological Products Business Description

Address No. 2, Shuangqiao Road, Chaoyang District, Beijing, CHN, 100024
Beijing Tiantan Biological Products Corp Ltd uses healthy human plasma and specifically immunized human plasma as raw materials and adopts genetic recombination technology to develop and produce blood products and engage in the blood product business. The company's main products include human albumin, human immunoglobulin (pH4) for intravenous injection, human hepatitis B immunoglobulin, human immunoglobulin, human rabies immunoglobulin, human histamine immunoglobulin, and others.
69GF Score

Get the complete analysis for SHSE:600161

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥12.78
Price
¥22.93
GF Value